"It’s remarkable that since the launch of our best-selling IBS-C and CIC product in 2012, LINZESS continues as a powerhouse brand experiencing accelerated demand and widespread acceptance in the GI community. "We remain highly confident we are well on our way to achieving our vision of becoming the country’s leading GI healthcare company, as evidenced by another stellar quarter of performance and profitability," said Tom McCourt, chief executive officer of Ironwood.
(Nasdaq: IRWD), a GI-focused healthcare company, today reported financial results for third quarter 2021. to acquire an exclusive license to develop and commercialize, in the U.S., CNP-104 for the treatment of primary biliary cholangitis (PBC) –īOSTON, November 04, 2021-( BUSINESS WIRE)- Ironwood Pharmaceuticals, Inc. – Expands pipeline by entering into an option agreement with COUR Pharmaceuticals Development Company, Inc. – GAAP net income of $56 million and adjusted EBITDA of $65 million ended Q3 2021 with $574 million in cash and cash equivalents – LINZESS collaboration revenue of $100 million –
net sales of $253 million, an increase of 5% year-over-year – – LINZESS ® (Iinaclotide) prescription demand growth increased 12% year-over-year LINZESS U.S.
0 kommentar(er)
